INDV (Indivior Pharmaceuticals) Beneish M-Score: -0.83 (As of Jun. 25, 2026)


INDV Indivior Pharmaceuticals Inc INDV
75 GF Score
Price $41.48
GF Value $22.99
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Indivior Pharmaceuticals Beneish M-Score?

Indivior Pharmaceuticals INDV +3.80% 75 Beneish M-Score is -0.83 as of Jun. 25, 2026. GuruFocus rates INDV with a GF Score™ of 75/100 and a GF Value™ of $22.99 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 911 Drug Manufacturers companies, Indivior Pharmaceuticals ranks worse than 92.32% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -0.83 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Indivior Pharmaceuticals's Beneish M-Score or its related term are showing as below:

INDV' s Beneish M-Score Range Over the Past 10 Years
Min: -3.81   Med: -2.48   Max: -0.83
Current: -0.83

During the past 13 years, the highest Beneish M-Score of Indivior Pharmaceuticals was -0.83. The lowest was -3.81. And the median was -2.48.


Indivior Pharmaceuticals Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Indivior Pharmaceuticals's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Indivior Pharmaceuticals Beneish M-Score Chart

Indivior Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.68 -2.38 -1.94 -1.71 -1.52

Indivior Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.52 -3.05 -2.96 -1.52 -0.83

INDV vs AMRX, KNSA, LQDA: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Indivior Pharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Indivior Pharmaceuticals Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Indivior Pharmaceuticals's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Indivior Pharmaceuticals's Beneish M-Score falls into.


INDV
75GF Score
Indivior Pharmaceuticals Inc INDV
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Indivior Pharmaceuticals Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Indivior Pharmaceuticals for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9504+0.528 * 0.9816+0.404 * 1.152+0.892 * 1.1025+0.115 * 1.7164
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9432+4.679 * 0.319131-0.327 * 1.0915
=-0.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was $285 Mil.
Revenue was 317 + 358 + 314 + 302 = $1,291 Mil.
Gross Profit was 277 + 291 + 231 + 250 = $1,049 Mil.
Total Current Assets was $667 Mil.
Total Assets was $1,197 Mil.
Property, Plant and Equipment(Net PPE) was $179 Mil.
Depreciation, Depletion and Amortization(DDA) was $19 Mil.
Selling, General, & Admin. Expense(SGA) was $626 Mil.
Total Current Liabilities was $779 Mil.
Long-Term Debt & Capital Lease Obligation was $500 Mil.
Net Income was 89 + 102 + 42 + 18 = $251 Mil.
Non Operating Income was -18 + -2 + 0 + 0 = $-20 Mil.
Cash Flow from Operations was -9 + -221 + -39 + 158 = $-111 Mil.
Total Receivables was $272 Mil.
Revenue was 266 + 299 + 307 + 299 = $1,171 Mil.
Gross Profit was 222 + 251 + 241 + 220 = $934 Mil.
Total Current Assets was $883 Mil.
Total Assets was $1,375 Mil.
Property, Plant and Equipment(Net PPE) was $142 Mil.
Depreciation, Depletion and Amortization(DDA) was $28 Mil.
Selling, General, & Admin. Expense(SGA) was $602 Mil.
Total Current Liabilities was $1,005 Mil.
Long-Term Debt & Capital Lease Obligation was $341 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(285 / 1291) / (272 / 1171)
=0.220759 / 0.23228
=0.9504

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(934 / 1171) / (1049 / 1291)
=0.797609 / 0.812548
=0.9816

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (667 + 179) / 1197) / (1 - (883 + 142) / 1375)
=0.293233 / 0.254545
=1.152

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1291 / 1171
=1.1025

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(28 / (28 + 142)) / (19 / (19 + 179))
=0.164706 / 0.09596
=1.7164

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(626 / 1291) / (602 / 1171)
=0.484895 / 0.514091
=0.9432

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((500 + 779) / 1197) / ((341 + 1005) / 1375)
=1.068505 / 0.978909
=1.0915

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(251 - -20 - -111) / 1197
=0.319131

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Indivior Pharmaceuticals has a M-score of -0.83 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -0.83 mean?
Indivior Pharmaceuticals (INDV) has a Beneish M-Score of -0.83 as of Jun. 25, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Indivior Pharmaceuticals and its competitors. According to the industry distribution chart, Indivior Pharmaceuticals ranks #841 out of 911 companies in the Drug Manufacturers industry, placing it in the top 92.3%.
Is Indivior Pharmaceuticals' Beneish M-Score too high?
Indivior Pharmaceuticals' current Beneish M-Score is -0.83. Based on the distribution chart, Indivior Pharmaceuticals ranks #841 out of 911 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Indivior Pharmaceuticals has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Indivior Pharmaceuticals' Beneish M-Score compare to AMRX and KNSA?
According to the Drug Manufacturers industry distribution chart, Indivior Pharmaceuticals ranks #841 out of 911 companies for Beneish M-Score. This places Indivior Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Indivior Pharmaceuticals and its competitors. Indivior Pharmaceuticals's current Beneish M-Score is -0.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indivior Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Indivior Pharmaceuticals (INDV) is currently considered Significantly Overvalued. The stock's GF Value™ is $22.99, compared to a current price of $41.48 — trading 80.4% above its estimated fair value. The current Beneish M-Score is -0.83. Indivior Pharmaceuticals' overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Indivior Pharmaceuticals (INDV), the current Beneish M-Score is -0.83 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Indivior Pharmaceuticals (INDV) Overvalued in 2026?

Based on GuruFocus' analysis, Indivior Pharmaceuticals stock appears to be overvalued. The current stock price of $41.48 is trading 80.4% above its estimated GF Value™ of $22.99. GuruFocus considers Indivior Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for INDV:

  • Beneish M-Score: -0.83
  • GF Value™: $22.99 vs. price of $41.48 (80.4% above fair value)
  • GF Score™: 75/100 with 6 warning signs

No single metric tells the full story. See the INDV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Indivior Pharmaceuticals Business Description

Other Exchanges E7P:Germany
Address 10710 Midlothian Turnpike, Suite 125, North Chesterfield, Richmond, VA, USA, 23235
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
75GF Score

Get the complete analysis for INDV

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$41.48
Price
$22.99
GF Value